Akademik Veri Yönetim Sistemi
Cerrahpaşa Medical Journal, sa.1, ss.1-9, 2026 (TRDizin)
Objective: To evaluate the feasibility and safety of bronchial artery embolization (BAE) as a first-line endovascular treatment in patients presenting to the clinic with massive hemoptysis. Methods: In this retrospective single-center study, 43 patients (mean age: 55.6 ± 17.6 years) who underwent BAE for massive hemoptysis between 2016 and 2022 were analyzed. Patient demographics, indications, angiographic findings, embolization materials used, procedure success rates, recurrence rates (early and late), complications, and mortality rates were evaluated during a mean follow-up period of 24 months (range: 6-72 months). Results: Technical success was achieved in 97% of patients, while early clinical success was observed in 95.3%. Early recurrence occurred in 7.1% of cases and late recurrence in 16.2%. The most common etiologies in recurrent cases were recanalization and systemic collaterals. The complication rate was 18.6% and the most common complication was transient chest pain; 1 patient had transient paraplegia. The mortality rate was 7%. Conclusion: Bronchial artery embolization appears to be an effective and relatively safe intervention for the management of massive hemoptysis, demonstrating high technical and clinical success rates with acceptable complication and recurrence rates. Identification and management of non-bronchial systemic collaterals and selection of embolic agents on a case-by-case basis are important to minimize recurrence and improve long-term outcomes.